Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
|ClinicalTrials.gov Identifier: NCT03448458|
Recruitment Status : Recruiting
First Posted : February 28, 2018
Last Update Posted : February 28, 2018
|Condition or disease||Intervention/treatment||Phase|
|Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IV Prostate Cancer AJCC v7||Procedure: CT (Computed Tomography) Drug: Gallium Ga 68-DOTATATE Procedure: Positron Emission Tomography||Phase 2|
Establish the feasibility of using gallium Ga 68-DOTATATE (68Ga-DOTATATE) PET as a predictive imaging biomarker for neuroendocrine transdifferentiation in prostate cancer.
Correlate progression of disease with degree of uptake on 68Ga-DOTATATE PET examination.
Patients receive gallium Ga 68-DOTATATE intravenously (IV). Within 55-70 minutes, patients undergo PET/CT.
After completion of study, patients are followed up for at least 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Molecular Imaging With Ga-68 DOTATATE PET to Investigate Neuroendocrine Differentiation in Prostate Cancer Patients|
|Actual Study Start Date :||February 22, 2018|
|Estimated Primary Completion Date :||February 28, 2022|
|Estimated Study Completion Date :||February 28, 2022|
Experimental: Gallium Ga 68-DOTATATE PET/CT
Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
Procedure: CT (Computed Tomography)
Other Names:Drug: Gallium Ga 68-DOTATATE
Other Names:Procedure: Positron Emission Tomography
- Gallium Ga 68-DOTATATE uptake [ Time Frame: Up to 1 year post-therapy ]Will be summarized using descriptive statistics. The inter-rater agreement will be assessed by Kappa statistics or intra-class correlation coefficient. The degree of uptake will be plotted against length of time to progress, and the association will be described by Spearman correlation coefficient with 95% confidence interval (CI). In addition, will dichotomize degree of update by median and defined it as high vs. low, and apply Wilcoxon rank sum test or Fisher exact test wherever appropriate.
- Progression free survival [ Time Frame: Date of enrollment to date of progression (radiographic progression or clinical deterioration) or death, or last follow up if event free, assessed up to 1 year ]Will be associated with 68Ga-DOTATATE uptake. Will be described by Kaplan-Meier method along log-rank p-value.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03448458
|Contact: Mehmet Asim Bilen, MDfirstname.lastname@example.org|
|Contact: Ephraim Parent, MD, PhDemail@example.com|
|United States, Georgia|
|Emory University Hospital/Winship Cancer Institute||Recruiting|
|Atlanta, Georgia, United States, 30322|
|Contact: Wilena Session 404-778-3448 firstname.lastname@example.org|
|Principal Investigator:||Mehmet Asim Bilen, MD||Emory University|